An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Levoketoconazole (Primary)
- Indications Cushing syndrome
- Focus Registrational; Therapeutic Use
- Acronyms OPTICS
- Sponsors Strongbridge Biopharma
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.
- 10 Oct 2018 Planned initiation date changed from 20 Aug 2018 to 20 Oct 2018.
- 17 Aug 2018 New trial record